Sonoma Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 03, 2026, SNOA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.31 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 4.41 million, with a --% difference. The market reacted with a -0.93% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 3 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 4.68 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Sonoma Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Sonoma Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Sonoma Pharmaceuticals, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -0.93%, changed from $3.23 before the earnings release to $3.20 the day after.
When is Sonoma Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Jun 15, 2026.
What are the forecasts for Sonoma Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analysts, Sonoma Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $4.68M for Q4 2026.